Get startedLog in
    Picture of Samsung Biologics Co logo

    207940 — Samsung Biologics Co Income Statement

    0.000.00%
    kr flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Samsung Biologics Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    R2024
    December 31st
    2025
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:Annual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited Accounts
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue1,568,0073,001,2953,694,5893,497,1464,556,972
    Cost of Revenue
    Gross Profit726,4511,468,4481,802,7651,711,1852,516,640
    Selling / General / Administrative Expenses
    Research And Development
    Depreciation and Amortization
    Unusual Expense / Income
    Total Operating Expenses1,030,6971,952,5622,575,7502,176,4612,487,750
    Operating Profit537,3101,048,7331,118,8391,320,6852,069,222
    Gain / Loss on Sale of Assets
    Total Net Non Operating Interest Income / Expense
    Other Net Non Operating Costs
    Net Income Before Taxes561,2831,009,0251,119,9871,384,8692,118,631
    Provision for Income Taxes
    Net Income After Taxes393,589798,056857,6911,040,3021,614,330
    Net Income Before Extraordinary Items
    Extraordinary Items
    Net Income393,589798,056857,6911,083,3161,784,352
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income393,589798,056857,6911,083,3161,784,352
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS9,15916,48818,50722,51637,136
    Dividends per Share